$Foghorn Therapeutics (FHTX.US)$ Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update Monday, 28th April at 4:05 pm - FHD-909 (LY4050784) advancing in Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population - Preclinical synergistic anti-tumor activity of FHD-909 in combination with pembrolizumab and KRAS ...
$Foghorn Therapeutics (FHTX.US)$ Flagship Pioneering Announces Agreement Between Pioneering Medicines and Pfizer to Discover Potential Novel, Selective Inhibitors for Autoimmune Disease Tuesday, 1st April at 8:00 am Collaboration leverages Logica, a platform offering from Valo Health and Charles River that directly translates biological insights into optimized small molecules Sixth agreement signed under strategic partnership between Flagship Pioneering and Pfizer to accelerate discovery of...
NOTE! 1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice. 2. Do NOT open position WITHOUT chart confirmation, indicators, momentum. 3. Scale out and secure profits. 4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability. 5. I DO NOT give buy or sell advice 6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow) 7. NEVER be a blind follower. LASTLY, If yo...
$Foghorn Therapeutics (FHTX.US)$ Flagship Pioneering Unveils Lila Sciences to Build Superintelligence in Science Monday, 10th March at 11:29 am AI platform combined with autonomous labs will accelerate discovery across every domain of science Company has raised $200M in seed financing to further develop platform and build first AI Science Factories CAMBRIDGE, Mass., March 10, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Lila Sciences, a company ...
$Foghorn Therapeutics (FHTX.US)$Reuters· 2 mins ago Foghorn Therapeutics Inc. - Phase 1 Trial of Fhd-286 Showed Clinical Responses but Did Not Meet Threshold
3
Report
Daily Investors
:
Hey I started a Bio Tech group, I know your on the same exact thing. If you want in you can. It is only for Bio and Major Pharm. But just what iv put in their over the weekend and today. Def worth it, if you want in send me a FR and I'll add you in
Daily Investors
:
* Editas Medicine laid off 65% of its workforce after failing to find a partner for its reni-cel program. * Medtronic's latest PillCam completed its first patient procedure. * AbbVie acquired oral peptide biotech Nimble for $200 million. * Novartis paid PTC $1 billi...
Trytosaveabit
OPDaily Investors
:
Thank you! I’ll have to think it over. I’m so busy already that I’m not sure if I’ll be able to contribute much! But again thank you
$Foghorn Therapeutics (FHTX.US)$ Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities Monday, 16th December at 7:00 am Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients with relapsed and/or refractory AML; efficacy threshold not achieved to support continued development by Foghorn alone Company to prioritize investment into proprietary pipe...
$Foghorn Therapeutics (FHTX.US)$ NEWS Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
Report
No comment yet
Sign in to post a comment
Market Insights
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Foghorn Therapeutics Stock Forum
Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update
Monday, 28th April at 4:05 pm
- FHD-909 (LY4050784) advancing in Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population
- Preclinical synergistic anti-tumor activity of FHD-909 in combination with pembrolizumab and KRAS ...
Major Breakthrough: Pfizer Teams With Flagship to Develop AI-Driven Autoimmune Treatments
Flagship Pioneering Announces Agreement Between Pioneering Medicines and Pfizer to Discover Potential Novel, Selective Inhibitors for Autoimmune Disease
Tuesday, 1st April at 8:00 am
Collaboration leverages Logica, a platform offering from Valo Health and Charles River that directly translates biological insights into optimized small molecules
Sixth agreement signed under strategic partnership between Flagship Pioneering and Pfizer to accelerate discovery of...
Breakthrough Cancer Drug FHD-909 Reveals Powerful Combination Potential Against Lung Cancer
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If yo...
Flagship Pioneering Unveils Lila Sciences to Build Superintelligence in Science
Monday, 10th March at 11:29 am
AI platform combined with autonomous labs will accelerate discovery across every domain of science
Company has raised $200M in seed financing to further develop platform and build first AI Science Factories
CAMBRIDGE, Mass., March 10, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Lila Sciences, a company ...
Foghorn Therapeutics Inc. - Phase 1 Trial of Fhd-286 Showed Clinical Responses but Did Not Meet Threshold
Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities
Monday, 16th December at 7:00 am
Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients with relapsed and/or refractory AML; efficacy threshold not achieved to support continued development by Foghorn alone
Company to prioritize investment into proprietary pipe...
NEWS
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
No comment yet